Genetic variations as predictors of outcome and toxicity in non-small-cell lung cancer patients undergoing chemoradiation or chemotherapy with platinum agents.

Genetic variations as predictors of outcome and toxicity in non-small-cell lung cancer patients undergoing chemoradiation or chemotherapy with platinum agents. - Pharmacogenetics lung cancer - PGx-Lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47255

Enrollment

350

Registered

2015-08-17

Start date

2016-02-16

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer Non-small-cell lung cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Diagnosed with NSCLC (stage II-IV) * Age *18 year * Received or starting with chemoradiation or chemotherapy with platinating agents (carboplatin, cisplatin)

Exclusion criteria

Exclusion criteria: * Unable to give informed consent * Patients with cognitive impairment or those who are not able to read or write Dutch (because of difficulties in completing questionnaires)

Design outcomes

Primary

Measure	Time frame
Esophagitis (grade 1-4), nephrotoxicity (grade 1-4), neurotoxicity (grade 1-4) and genetic markers. All toxicities will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.0.	—

Secondary

Measure	Time frame
Survival time is defined as survival from date of diagnosis in months. Besides, patient-reported outcomes and quality of life will be compared at 4 points in time (before treatment, after 3 months of treatment, after 6 months and 1 year follow-up). Skeletel muscle mass measured on available (PET)CT scans.	—

Countries

Netherlands

Outcome results